Table 1.
Baseline patient characteristics and demographics
| Danvatirsen monotherapy (cohort 1) N=5 |
Danvatirsen+durvalumab (cohort 2) N=6 |
Total N=11 |
|
| Sex | |||
| Male | 4 (80.0) | 4 (66.7) | 8 (72.7) |
| Age, median (range), years | 68.0 (41–73) | 67.0 (63–77) | 68.0 (41–77) |
| Weight, median (range), kg | 64.8 (61.4–91.6) | 63.9 (44.5–71.1) | 64.3 (44.5–91.6) |
| Body mass index, median (range), kg/m2 | 25.7 (21.9–34.7) | 22.3 (19.5–28.1) | 22.7 (19.5–34.7) |
| ECOG PS | |||
| 0 | 3 (60.0) | 5 (83.3) | 8 (72.7) |
| 1 | 2 (40.0) | 1 (16.7) | 3 (27.3) |
| Primary tumour location | |||
| Oesophagus | 2 (40.0) | 3 (50.0) | 5 (45.3) |
| Colon | 2 (40.0) | 1 (16.7) | 3 (27.3) |
| Rectum | 1 (20.0) | 0 | 1 (9.1) |
| Uterine corpus | 0 | 1 (16.7) | 1 (9.1) |
| Unknown | 0 | 1 (16.7) | 1 (9.1) |
| Tumour grade | |||
| Well-differentiated | 1 (20.0) | 1 (16.7) | 2 (18.2) |
| Moderately differentiated | 3 (60.0) | 2 (33.3) | 5 (45.5) |
| Poorly differentiated | 0 | 1 (16.7) | 1 (9.1) |
| Not assessable | 0 | 2 (33.3) | 2 (18.2) |
| High grade | 1 (20.0) | 0 | 1 (9.1) |
| Histology type | |||
| Squamous cell carcinoma of the oesophagus | 2 (40.0) | 3 (50.0) | 5 (45.5) |
| Tubular adenocarcinoma of the colon | 2 (40.0) | 1 (16.7) | 3 (27.3) |
| Adenocarcinoma* | 1 (20.0) | 1 (16.7) | 2 (18.2) |
| Endometrioid adenocarcinoma | 0 | 1 (16.7) | 1 (9.1) |
| Overall disease classification† | |||
| Metastatic | 5 (100.0) | 6 (100.0) | 11 (100.0) |
| Locally advanced | 1 (20.0) | 1 (16.7) | 2 (18.2) |
| No evidence of disease | 0 | 0 | 0 |
| Missing | 0 | 0 | 0 |
Data are n (%).
*One case of adenocarcinoma of the rectum in cohort 1 and one case of adenocarcinoma located in ‘other’ in cohort 2.
†Classifications were not mutually exclusive.
ECOG PS, Eastern Cooperative Oncology Group Performance Status.